Orexo

Updated on Dec 24, 2024

Edit

Comment

Type Public Area served Worldwide Products See list Revenue 429.4 million SEK (2013) Number of employees 108 (2013)		Industry Pharmaceutical Key people Nikolaj Sørensen(CEO) Headquarters Sweden Founded 1995 Net income 154.9 million SEK (2013)

Traded as Nasdaq Stockholm: ORXOTCQX: ORXOY Stock price ORX (STO) SEK 29.10 -0.30 (-1.02%)24 Mar, 5:29 PM GMT+1 - Disclaimer Subsidiaries Pyrinox AB, ProStrakan AB, PharmaKodex Ltd., Pharmacall AB, Orexo US Inc Profiles LinkedIn

Orexo is a pharmaceutical company based in Uppsala, Sweden initially financed with venture capital provided by HealthCap.

The company was founded in 1995 and their first product Diabact UBT, a breath test for diagnosing the causative agent of stomach ulcers (Helicobacter pylori), was introduced in 2000. In 2003, the company adopted the name Orexo and in 2005 the company was listed on the Stockholm Stock Exchange.

Products

Abstral, for the treatment of breakthrough cancer pain. It was approved in 2008 in Europe and for marketing in United States by the FDA in 2011.

Edluar, for the treatment of short-term insomnia. FDA approved in 2009.

Zubsolv a dissovable tablet which combines the drugs buprenorphine and naloxone and treats opioid dependency and addiction. FDA approved in July 2013. Launched in the United States in September 2013

References

Orexo Wikipedia

(Text) CC BY-SA